Cutler Investment Counsel LLC Has $10.61 Million Stake in Medtronic PLC $MDT

Cutler Investment Counsel LLC decreased its position in Medtronic PLC (NYSE:MDT) by 0.3% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 120,767 shares of the medical technology company’s stock after selling 346 shares during the period. Medtronic comprises about 1.2% of Cutler Investment Counsel LLC’s investment portfolio, making the stock its 29th biggest holding. Cutler Investment Counsel LLC’s holdings in Medtronic were worth $10,611,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDT. Brighton Jones LLC lifted its position in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. GAMMA Investing LLC lifted its position in Medtronic by 41.1% in the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock worth $1,427,000 after buying an additional 4,626 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Medtronic by 11.2% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 531,059 shares of the medical technology company’s stock worth $47,721,000 after buying an additional 53,340 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in Medtronic in the 1st quarter worth approximately $75,000. Finally, Dynamic Advisor Solutions LLC lifted its position in Medtronic by 49.6% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 29,764 shares of the medical technology company’s stock worth $2,675,000 after buying an additional 9,873 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MDT shares. The Goldman Sachs Group cut their target price on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating for the company in a research report on Wednesday, October 1st. UBS Group raised their price target on shares of Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 20th. Robert W. Baird raised their price target on shares of Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, August 20th. Daiwa Capital Markets raised their price target on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $102.41.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Up 0.2%

Medtronic stock opened at $95.63 on Tuesday. The company has a market capitalization of $122.66 billion, a P/E ratio of 26.34, a P/E/G ratio of 2.51 and a beta of 0.78. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm’s fifty day simple moving average is $93.68 and its 200-day simple moving average is $88.80.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.